The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2013Comparative Characterization of Alpha-synuclein Species and Identification of Antibodies that Detect and Capture Alpha-synuclein
Objective/Rationale:
The identification and validation of biomarkers of Parkinson’s disease (PD) is crucial for diagnosing the disease early, monitoring disease progression, designing... -
Cognition Biomarkers, 2013Validation of Computer-based Saccade Measures as a Biomarker for Neurocognitive Changes in Parkinson's Disease
Objective/Rationale:
Saccades are fast eye movements that shift visual focus for tasks like reading, visual searching and coordinating safe movement. Research has shown that the speed, accuracy and... -
Cognition Biomarkers, 2013Assessment of Plasma Glucosylceramides and Ceramides as Biomarkers of Cognitive Impairment in Parkinson's Disease
Objective/Rationale:
Metabolism of the lipids glucosylceramide and ceramide is altered in Parkinson’s disease (PD). GBA mutations in this pathway, causing a build-up of glucosylceramide, increase the... -
Research Grant, 2013Longitudinal Characterization of G2019S Models: Physiological and Behavioral Analyses of Dopamine and Glutamate Systems
Objective/Rationale:
It is likely in disease states that brain cells suffer long periods of dysfunction before they die. By studying the early effects of Parkinson’s disease (PD) gene mutations upon... -
LRRK2 Pharmacodynamic Assays, 2013Monocyte Monitoring in LRRK2-associated Parkinson’s Disease
Objective/Rationale:
LRRK2 variants significantly contribute to the development of familial and sporadic Parkinson’s disease (PD). However, it is not yet understood how LRRK2 mutations cause cellular... -
Research Grant, 2013Evaluation of a LRRK2 Inhibitor in the Partial 6-OHDA-lesioned Model of Parkinson’s Disease
Objective/Rationale:
Mutations in the LRRK2 gene are the most common cause of familial Parkinson’s disease (PD). The existing human genetic, cell-based and model data suggest that LRRK2 kinase...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.